Clinical pharmacology in leishmaniasis: treatment optimization of a neglected disease
Dorlo, T.P.C.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
## Contents

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PREFACE</td>
<td>11</td>
</tr>
<tr>
<td><strong>CHAPTER 1</strong></td>
<td>17</td>
</tr>
<tr>
<td>1.1</td>
<td>19</td>
</tr>
</tbody>
</table>
| Miltefosine: a review of its pharmacology and therapeutic efficacy (Review)  
*Journal of Antimicrobial Chemotherapy* 2012; 67: 2576-97 |
| **CHAPTER 2** | 61   |
| 2.1 | 63   |
| Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry  
*Journal of Chromatography B* 2008; 865: 55-62 |
| **CHAPTER 3** | 83   |
| 3.1 | 85   |
| Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients  
*Antimicrobial Agents and Chemotherapy* 2008; 52: 2855-60 |
| 3.2 | 101  |
| Optimal dosing of miltefosine in children and adults with visceral leishmaniasis  
*Antimicrobial Agents and Chemotherapy* 2012; 56: 3864-72 |
| 3.3 | 121  |
| Translational pharmacokinetic modeling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine  
*Journal of Antimicrobial Chemotherapy* 2012; 67: 1996-2004 |
| **CHAPTER 4** | 141  |
| 4.1 | 143  |
| Dynamics of parasite clearance in cutaneous leishmaniasis patients  
*PLoS Neglected Tropical Diseases* 2011; 5: e1436 |
| 4.2 | 155  |
| AmBisome® for visceral leishmaniasis patients in East Africa: a multi-centre randomized trial  
*Submitted for publication* |
Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure
Submitted for publication

Biomarkers to monitor therapeutic response in leishmaniasis
(Review)
Submitted for publication

CHAPTER 5  IMPACT OF THE QUALITY OF MEDICINES AND GUIDELINES

5.1  Characterization and identification of miltefosine in suspected counterfeit capsules
Analyst 2012; 137: 1265-74

5.2  A poor–quality drug for the treatment of visceral leishmaniasis: a case report and appeal
PLoS Neglected Tropical Diseases 2012; 6: e1544

5.3  Quality of medicines for neglected tropical diseases: an urgent matter
British Medical Journal 2012; 345: e7518 (shortened & updated version)

5.4  Universal access to quality medicines: prioritisation of a priori solutions
The Lancet Infectious Diseases 2012; 12: 829-30

5.5  Pentamidine dosage: a base/salt confusion
PLoS Neglected Tropical Diseases 2008; 2: e225

CHAPTER 6  CONCLUSIONS & PERSPECTIVES

SUMMARY

NEDERLANDSE SAMENVATTING (DUTCH SUMMARY)

ACKNOWLEDGEMENTS / DANKWOORD

LIST OF PUBLICATIONS

ABOUT THE AUTHOR